A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Recruiting · NCT07235202 · Registry updated 2026-05-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 1 / Phase 2 | 2026-05-26 | NCT07235202 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen Majory Biotechnology Co., Ltd. | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tsinghua Changgung Hospital | Beijing | China | 31 |
| Harbin Medical University Cancer Hospital | Harbin | China | 102 |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou | China | 22 |
| The First Hospital of Jilin University | Changchun | China | 1 |